Literature DB >> 32052404

Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.

Adrian Săftoiu1,2, Cesare Hassan3, Miguel Areia4,5, Manoop S Bhutani6, Raf Bisschops7, Erwan Bories8, Irina M Cazacu1,6, Evelien Dekker9, Pierre H Deprez10, Stephen P Pereira11, Carlo Senore12, Riccardo Capocaccia13, Giulio Antonelli3, Jeanin van Hooft9, Helmut Messmann14, Peter D Siersema15, Mario Dinis-Ribeiro5,16, Thierry Ponchon17.   

Abstract

In Europe at present, but also in 2040, 1 in 3 cancer-related deaths are expected to be caused by digestive cancers. Endoscopic technologies enable diagnosis, with relatively low invasiveness, of precancerous conditions and early cancers, thereby improving patient survival. Overall, endoscopy capacity must be adjusted to facilitate both effective screening programs and rigorous control of the quality assurance and surveillance systems required. 1 : For average-risk populations, ESGE recommends the implementation of organized population-based screening programs FOR COLORECTAL CANCER: , based on fecal immunochemical testing (FIT), targeting individuals, irrespective of gender, aged between 50 and 75 years. Depending on local factors, namely the adherence of the target population and availability of endoscopy services, primary screening by colonoscopy or sigmoidoscopy may also be recommendable. 2 : In high-risk populations, endoscopic screening FOR GASTRIC CANCER: should be considered for individuals aged more than 40 years. Its use in countries/regions with intermediate risk may be considered on the basis of local settings and availability of endoscopic resources. 3 : For esophageal and pancreatic cancer, endoscopic screening may be considered only in high-risk individuals:- FOR SQUAMOUS CELL CARCINOMA: , in those with a personal history of head/neck cancer, achalasia, or previous caustic injury; - FOR BARRETT'S ESOPHAGUS (BE)-ASSOCIATED ADENOCARCINOMA: , in those with long-standing gastroesophageal reflux disease symptoms (i. e., > 5 years) and multiple risk factors (age ≥ 50 years, white race, male sex, obesity, first-degree relative with BE or esophageal adenocarcinoma [EAC]). - FOR PANCREATIC CANCER SCREENING: , endoscopic ultrasound may be used in selected high-risk patients such as those with a strong family history and/or genetic susceptibility. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2020        PMID: 32052404     DOI: 10.1055/a-1104-5245

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  19 in total

1.  Results of endoscopy in 35,525 patients with precancerous diseases of the gastrointestinal tract.

Authors:  Tong Meng; Yujia Wu; Xing Chen; Junhui Lu; Jing Fan; Jiang Bai
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

2.  UEG Week 2020 Oral Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

3.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

Review 4.  Highlighting the Undetectable - Fluorescence Molecular Imaging in Gastrointestinal Endoscopy.

Authors:  Judith A Stibbe; Petra Hoogland; Friso B Achterberg; Derek R Holman; Raoul S Sojwal; Jacobus Burggraaf; Alexander L Vahrmeijer; Wouter B Nagengast; Stephan Rogalla
Journal:  Mol Imaging Biol       Date:  2022-06-28       Impact factor: 3.488

Review 5.  Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.

Authors:  Amrit K Kamboj; David A Katzka; Prasad G Iyer
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21

6.  Feasibility of Endoscopic Screening for Upper Gastrointestinal Malignancy in a Comprehensive Health Checkup.

Authors:  Sayaka Sato; Saki Fushimi; Yuta Tahata; Hiroya Mizutamari; Nobuya Mimori; Yuhei Kato; Yohei Horikawa
Journal:  Intern Med       Date:  2020-12-15       Impact factor: 1.271

Review 7.  Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions.

Authors:  Katerina G Oikonomou; Panagiotis Papamichalis; Tilemachos Zafeiridis; Maria Xanthoudaki; Evangelia Papapostolou; Asimina Valsamaki; Konstantinos Bouliaris; Michail Papamichalis; Marios Karvouniaris; Panagiotis J Vlachostergios; Apostolia-Lemonia Skoura; Apostolos Komnos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 8.  A risk-stratified approach to colorectal cancer prevention and diagnosis.

Authors:  Mark A Hull; Colin J Rees; Linda Sharp; Sara Koo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-16       Impact factor: 46.802

Review 9.  Are Volatile Organic Compounds Accurate Markers in the Assessment of Colorectal Cancer and Inflammatory Bowel Diseases? A Review.

Authors:  Filippo Vernia; Marco Valvano; Stefano Fabiani; Gianpiero Stefanelli; Salvatore Longo; Angelo Viscido; Giovanni Latella
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

10.  Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH-AARP Diet and Health Study cohort.

Authors:  Shao-Ming Wang; Neal D Freedman; Hormuzd A Katki; Charles Matthews; Barry I Graubard; Lisa L Kahle; Christian C Abnet
Journal:  Cancer       Date:  2021-02-22       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.